-
Professor Wang Kun: Interpretation of the key points of the 2021 CSCO BC diagnosis and treatment guidelines-HER2-positive early breast cancer neoadjuvant treatment
Time of Update: 2021-04-23
Professor Wang Kun: With the continuous updating of various clinical trials and new treatment concepts in the field of breast cancer, I believe that in the next few years, more and more good drugs will emerge in the field of neoadjuvant therapy.
-
Major gastric cancer treatment FDA approves the first first-line immunotherapy today
Time of Update: 2021-04-23
▎The content team editor of WuXi AppTec today, the US FDA announced that it has approved Bristol-Myers Squibb (BMS)'s blockbuster PD-1 inhibitor Opdivo (nivolumab) in combination with chemotherapy as a treatment for advanced or metastatic gastric cancer and gastroesophageal combination First-line therapy for GEJ cancer and esophageal adenocarcinoma.
-
Focusing on the diagnosis and treatment of small cell lung cancer, what kind of spark will come from radiotherapy and immunotherapy?
Time of Update: 2021-04-23
Professor Bi Nan: Some studies have found that some patients with extensive-stage small cell lung cancer have benefited from OS after chest radiotherapy.
Professor Song Yongchun: For patients with small cell lung cancer, radiotherapy is a very important treatment, but it is also necessary to pay attention to complications, such as pneumonia.
-
Professor Huang He: Another breakthrough in the treatment of B-NHL with new CAR-T cells|The First National Lymphocytic Disease Conference of Chinese Medical Association
Time of Update: 2021-04-23
2. CD19/CD22 sequential CAR-T cell therapy In addition, Professor Huang He introduced that the team of Professor Zhou Jianfeng from Tongji Hospital of Huazhong University of Science and Technology used CD19-CAR-T cells sequential CD22-CAR-T cells to treat relapsed/refractory B Cell tumor patients have also achieved good results: CD19/CD22 CAR-T cells have been expanded significantly, the overall response rate (ORR) is 72.
-
First-line treatment of advanced gastric cancer!
Time of Update: 2021-04-23
Recent popular reports from Yimaike ★ Nanjing · Big coffee gathered in May 2021 nucleic acid drug development forum announced schedule ★ May Nanjing 2021 nucleic acid drug development forum is about
-
Molecular Cancer | Soochow University Zhang Lifeng/Chen Yan discovered the key role of circular RNA in triple-negative breast cancer
Time of Update: 2021-04-23
iNature chemotherapy resistance is the main reason for clinical treatment failure and poor prognosis of triple negative breast cancer (TNBC).
On March 1, 2021, Zhang Lifeng and Chen Yan from Soochow University published an online report titled "CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K in Molecular Cancer (IF=15.
-
Verbutuximab adds another indication!
Time of Update: 2021-04-23
The ALCANZA study is an international, multi-center, randomized, open-label Phase III trial, carried out in 52 medical centers in 13 countries/regions around the world, to evaluate the use of new drugs BV and traditional therapies in patients with CD30-positive CTCL The efficacy and safety of [7].
-
2021 CSCO Breast Cancer Guidelines: Interpretation of the updated key points of HER2+ neoadjuvant treatment for early breast cancer | 2021 CSCO BC
Time of Update: 2021-04-23
In view of the fact that the concept of “neoadjuvant treatment for T1c patients” has not been verified by clinical research and practice, the CSCO breast cancer guidelines still adopt the most advanced and feasible selection criteria currently considered, that is, for HER2+, T≥2 or N≥1 The patient was given neoadjuvant therapy.
-
Survival from a dead end: advanced triple-negative breast cancer discovered driver gene mutations, targeted therapy to relieve the condition
Time of Update: 2021-04-23
Two years after the operation, the patient was re-examined and found suspicious lesions in the right lung, which was confirmed by needle biopsy as a metastasis of triple-negative breast cancer.
Verofenib is a targeted drug for the BRAF gene V600E mutation site, but it has not been indicated for triple-negative breast cancer.
-
After two relapses!
Time of Update: 2021-04-23
Professor Zhang Bingzhong: Most patients with ovarian cancer can achieve complete remission after the initial treatment, but about 80% of patients will relapse, with an average recurrence time of about 18 months.
-
Nature's new research deeply reveals the crazy sugar phagocytosis effect of tumor microenvironment
Time of Update: 2021-04-23
In 2020, Science Signaling and Nature Review Cancer have successively published articles to further clarify the mechanism of tumor Warburg effect, and explore the specificity of various gene mutations or autoimmune functions and tumor cells The relationship between sex metabolism helps to better develop tumor treatment methods or enhance the efficacy of drugs.
-
Why does the risk of colorectal cancer increase?
Time of Update: 2021-04-23
A new study recently published in the journal Clinical Nutrition reveals that a type of food is associated with an increased risk of colorectal cancer.
Researchers analyzed that the association between eating ultra-processed foods and increased risk of colorectal cancer may be related to many reasons.
-
Big data of 3.5 million people reveal that obesity is associated with the risk of 26 cancers
Time of Update: 2021-04-23
5 million people showed that obese people with a higher body mass index (BMI) have an increased risk of 12 cancers, and among non-smokers, BMI is also positively correlated with the risk of blood cancer and head and neck cancer.
-
99% of cervical cancers are related to TA!
Time of Update: 2021-04-23
Professor Zhou Qi talks with patients with cervical small-cell neuroendocrine cancer, from recurrence prevention to treatment of adverse reactions of radiotherapy and chemotherapy.
-
Top 10 questions that patients with pancreatic cystic tumors most want to know |
Time of Update: 2021-04-23
Professor Xu Xiaowu: In terms of surgical operation methods, traditional pancreatic surgery focuses on open surgery, but minimally invasive surgery such as laparoscopic surgery and robotic surgery has developed rapidly in the past 20 years.
-
The first adjuvant therapy for early lung cancer: AstraZeneca's EGFR-targeting drug Tagrisso was approved in China
Time of Update: 2021-04-23
This is the third indication that Teresa has been approved in China, and it is also another important achievement of this product as an adjuvant therapy for lung cancer after it was approved in the United States in December last year for the adjuvant treatment of early-stage EGFR-mutant lung cancer patients.
-
Express | Innovative first-line therapy for gastric cancer is recognized as a breakthrough therapy by FDA, Zai Lab owns rights in Greater China
Time of Update: 2021-04-23
▎The content team editor of WuXi AppTec today, Amgen announced that the US FDA granted its research FGFR2b antibody therapy bemarituzumab breakthrough therapy designation, combined with chemotherapy, for the first-line treatment of HER2-negative locally advanced or metastatic gastric cancer And gastroesophageal junction (GEJ) cancer patients.
-
Professor Han Weidong’s team issued a paper: The total remission rate reached 95%, and decitabine combined with PD-1 significantly improved the clinical outcome of patients with classic Hodgkin’s lymphoma | Yimai Meng broke the news
Time of Update: 2021-04-23
Recently (April 5, 2021), the Journal for ImmunoTherapy of Cancer (JITC) published online a clinical research paper by Professor Han Weidong’s team at the PLA General Hospital, entitled "Improved clinical outcome in a randomized phase II study" of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma".
-
Prof. Yingying Xu: From population selection to plan formulation, "re-understanding" of neoadjuvant treatment for breast cancer | 2021 CSCO BC
Time of Update: 2021-04-23
In addition, based on the results of the KATHERINE study, St Gallen experts support all HER2+ tumors with residual lesions after standard neoadjuvant treatment, even patients with residual invasive tumors less than 5 mm should receive adjuvant T-DM1 treatment.
-
Janssen Bipod high-throughput double antibody development platform
Time of Update: 2021-04-23
Schematic diagram of the production of symmetric and asymmetric bispecific antibodies (Document 1) The antibody standards suitable for clinical development include: relatively easy production, high stability and good activity.
